The 34 references in paper V. Dobronravov A., A. Smirnov V., I. Kayukov G., В. Добронравов А., А. Смирнов В., И. Каюков Г. (2009) “МНОГОГРАННАЯ АЛЬБУМИНУРИЯ: АСПЕКТЫ КЛИНИЧЕСКОГО ЗНАЧЕНИЯ // MANYSIDED ALBUMINURIA: ASPECTS OF CLINICAL VALUE” / spz:neicon:nefr:y:2009:i:3:p:33-38

1
Winocour P, Marshall S. Microalbuminuria. Cambridge University Press, Cambridge (UK), 1998, 1-10
(check this in PDF content)
2
Russo L, Bakris G, Comper W. Renal handling of albumin: A critical review of basic concepts and perspective. Am J Kidney Dis 2002 39: 899-919
(check this in PDF content)
3
National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002: S1-S266
(check this in PDF content)
4
Shlipak MG, Katz R, Sarnak MJ et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145: 237-246
(check this in PDF content)
5
Jaar BC, Khatib R, Plantinga L, Boulware LE, Powe N: Principles of screening of chronic kidney disease. Clin J Am Soc Nephrol 2008; 3:601-609
(check this in PDF content)
6
Stuveling EM, Bakker SJ, Hilige HX et al. Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol Dial Transplant 2005; 20: 497-508
(check this in PDF content)
7
Смирнов АВ, Добронравов ВА, Бодур-Ооржак АШ и др. Эпидемиология и факторы риска хронических болез­ ней почек: региональный уровень общей проблемы. Тер арх 2005; 77(6): 20-27
(check this in PDF content)
8
Halimi JM, Forhan A, Balkan B et al. Ig microalbuminuria an integrated risk marker for cardiovascular disease and insulin resistance in both men and women? J Cardiovasc Risk 2001; 8: 139-146
(check this in PDF content)
9
Orth SR. Smoking and the kidney. J Am Soc Nephrol 2002; 13: 1663-1672
(check this in PDF content)
10
Saweirs WWM, Goddard J. What are the best treatment for early chronic disease. Nephrol Dial Transplant 2007; 22 [suppl 9]: ix31-ix39
(check this in PDF content)
11
Williams PS, Fass G, Bone JM. Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. Q J Med 1988 67: 343-354
(check this in PDF content)
12
Remuzzi G, Bertani T. Is glom erulosclerosis a consequence of altered glom erular perm eability to macromolecules? Kidney Int 1990 38: 384-394
(check this in PDF content)
13
Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003 63:1468-1474
(check this in PDF content)
14
Jafar TH, Stark PC, Schmid CH et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001 60: 1131-1140
(check this in PDF content)
15
Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. Ann Int Med 2003 139: 244-252
(check this in PDF content)
16
Campese VM, Bianchi S, Bigazzi R. Is microalbuminuria a predictor of cardiovascular and renal disease in patients with essential hypertension? Curr Opin Nephrol Hypertens 2000 9: 143-147
(check this in PDF content)
17
Keane WF, Brenner BM, De Zeeuw D et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Kidney Int 2003 63:1499-1507
(check this in PDF content)
18
Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 2004; 65: 2309 -2320
(check this in PDF content)
19
Hunsicker LG, Atkins RC. Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int 2004; 66 [suppl 92]: 99-101
(check this in PDF content)
20
Mogensen CE. M icroalbum inuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984 310: 356-360
(check this in PDF content)
21
Mogensen CE. M icroalbum inuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987 31: 673-689
(check this in PDF content)
22
Verhave JC, Ganesvoort RT, Hillege HL et al. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int 2004; 66 [suppl 92]:18-21
(check this in PDF content)
23
Kannel WB, Stampfer MJ, Castelli WP, Verter J. The prognostic significance of proteinuria: The Framingham study. Am Heart J 1984 108: 1347-1352
(check this in PDF content)
24
Samuelsson O, W ilhelmsen L, Elm feldt D et al. Predictors of cardiovascular morbidity in treated hypertension: Results from the primary preventive trial in Goteborg, Sweden. J Hypertens 1985 3: 167-176
(check this in PDF content)
25
Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004 110: 921­ 927
(check this in PDF content)
26
Anavekar NS, Gans DJ, Berl T et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: A case for albuminuria. Kidney Int 2004 66 [suppl 92]: 50-55
(check this in PDF content)
27
Hillege HL, Janssen WM, Bak AA et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001 249: 519-526
(check this in PDF content)
28
Hillege HL, Fidler V, Diercks GF et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in the general population. Circulation 2002 106: 1777­ 1782
(check this in PDF content)
29
Romundstad S, Holmen J, Kvenild K et al. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: A 4.4-year follow -up study. The Nord- Trondelag Health Study (HUNT), Norway. Am J Kidney Dis 2003 42: 466-473
(check this in PDF content)
30
Yuyun MF, Khaw KT, Luben R et al. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol 2004 33: 189-198
(check this in PDF content)
31
Mann JF, Yi QL, Gerstein HC. Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney Int 2004; 66 [suppl 92]:59-62
(check this in PDF content)
32
Wachtell K, IbseN H, Olsen MH et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study. Ann Intern Med 2003 139: 901-906
(check this in PDF content)
33
Toto RD. Proteinuria and hypertensive nephrosclerosis in African-Americans. Kidney Int 66 [suppl 92]:102-104
(check this in PDF content)
34
Weir MR. M icroalbum inuria in type 2 diabetes: An im portant, overlooked cardiovascular risk factor. J Clin Hypertens 2004 6: 134-143 3 5 . Dinneen, SF, Gerstein, HC. The association of m icroalbum inuria and m ortality in non-insulin-dependent
(check this in PDF content)